Niven R Narain, Ph.D.

Co-Founder, President & Chief Executive Officer

Of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight.

He has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partners with industry, academia, and US and UK governments. Narain is most passionate about improving patient care and enabling increased access to innovative medicines to improved healthcare outcomes.

Boston Business Journal top 40 leaders under 40

Narain is an industry thought leader on precision medicine and drug development, frequently speaking at The Economist, Bloomberg, Financial Times, and Aspen Ideas meetings in addition to being featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal. He is inventor of Berg’s flagship Interrogative Biology® platform that created and guided a deep pipeline of products in oncology, diabetes, and CNS diseases, namely BPM 31510 in Phase 2 trials for cancer.

featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal.

Narain speaks at many international meetings on medicine and technology, and his research has been published in Nature Medicine and Cell among others with leading collaborators from academia, NIH, and DoD. He serves on the NASA/Gene Lab Steering Committee and works closely with DoD leadership on breast and prostate cancer initiatives. Narain is an inventor on a patent portfolio of over 550 pending patent applications and over 100 issued patents in the US and internationally, covering multiple disease areas and AI-based technologies.

Narain is an industry thought leader on precision medicine and drug development, frequently speaking at The Economist, Bloomberg, Financial Times, and Aspen Ideas meetings in addition to being featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal. He is inventor of Berg’s flagship Interrogative Biology® platform that created and guided a deep pipeline of products in oncology, diabetes, and CNS diseases, namely BPM 31510 in Phase 2 trials for cancer.

Executive Leadership